Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program was a global, longitudinal antimicrobial resistance surveillance network of more than 100 medical centers worldwide monitoring the susceptibility of meropenem and selected other broad-spectrum comparator agents. In 1999, and from 2000 through 2008, a total of 10 or 15 United States (USA) medical centers each forwarded 200 nonduplicate clinical isolates from serious infections to a central processing laboratory. Over the 10-year period of this surveillance program, the activity of meropenem and an average of 11 other antimicrobial agents were assessed against a total of 27 289 bacterial isolates using Clinical and Laboratory Standards Institute reference methods. Meropenem consistently demonstrated low resistance rates against Enterobacteriaceae species isolates through 2008 and did not exhibit a widespread change in resistance rates over the monitored interval. In fact, the incidence of emerging carbapenemase-producing (KPC-type) Klebsiella spp. showed a decline in 2008 compared to the steeply increasing rates observed from 2004 to 2007. Moreover, the KPC serine carbapenemases have spread to other Enterobacteriaceae species monitored by the MYSTIC Program. Greatest increases in antimicrobial resistance rates were observed for the fluoroquinolones (ciprofloxacin, levofloxacin) among all species monitored by the MYSTIC Program. Current susceptibility rates for meropenem when tested against prevalent pathogens were Pseudomonas aeruginosa (439 strains, 85.4% susceptible), Enterobacteriaceae (1537 strains, 97.3% susceptible), methicillin-susceptible staphylococci (460 strains, 100.0% susceptible), Streptococcus pneumoniae (125 strains, 80.2% at meningitis susceptibility breakpoints), other streptococci (159 strains, 90.0-100.0% susceptible), and Acinetobacter spp. (127 strains, 45.7% susceptible), the widest spectrum among beta-lactams tested in 2008 and throughout the last decade. Continued local surveillance of broad-spectrum agents following the completion of the MYSTIC Program (USA) appears critical to detect emerging resistances among pathogens causing the most serious infections requiring carbapenem agents.

[1]  M. Jacobs,et al.  The Alexander Project: the benefits from a decade of surveillance. , 2005, The Journal of antimicrobial chemotherapy.

[2]  Ronald N. Jones,et al.  An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. , 2005, Diagnostic microbiology and infectious disease.

[3]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[4]  P. Turner.  MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview. , 2000, The Journal of antimicrobial chemotherapy.

[5]  Ronald N. Jones,et al.  Comparison of 2002–2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance , 2009, The Annals of pharmacotherapy.

[6]  M. Roberts,et al.  Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. , 2009, The Journal of antimicrobial chemotherapy.

[7]  S. Ichiyama,et al.  PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams , 1996, Journal of clinical microbiology.

[8]  J. Quinn,et al.  SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens Strains , 2000, Antimicrobial Agents and Chemotherapy.

[9]  Ronald N. Jones,et al.  Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). , 2006, Diagnostic microbiology and infectious disease.

[10]  K. Bush,et al.  Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein , 1997, Antimicrobial agents and chemotherapy.

[11]  N. Woodford,et al.  In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. , 2007, The Journal of antimicrobial chemotherapy.

[12]  I. Kassis,et al.  Carbapenem Resistance Among Klebsiella pneumoniae Isolates Risk Factors, Molecular Characteristics, and Susceptibility Patterns , 2009, Infection Control & Hospital Epidemiology.

[13]  D. Nicolau,et al.  Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients , 2006, Journal of clinical pharmacology.

[14]  M. Ferraro,et al.  Plasmid-Mediated Carbapenem-Hydrolyzing Enzyme KPC-2 in an Enterobacter sp , 2004, Antimicrobial Agents and Chemotherapy.

[15]  R. Masterton,et al.  Determining the value of antimicrobial surveillance programs. , 2001, Diagnostic microbiology and infectious disease.

[16]  Ronald N. Jones,et al.  bla VIM-7, an Evolutionarily Distinct Metallo-β-Lactamase Gene in a Pseudomonas aeruginosa Isolate from the United States , 2004, Antimicrobial Agents and Chemotherapy.

[17]  M. Pfaller,et al.  Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme. , 2001, Diagnostic microbiology and infectious disease.

[18]  Neil Woodford,et al.  Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center , 2004, Antimicrobial Agents and Chemotherapy.

[19]  P. Turner.  MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. , 2009, Diagnostic microbiology and infectious disease.

[20]  Ronald N. Jones,et al.  Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). , 2004, The Journal of antimicrobial chemotherapy.

[21]  Ronald N. Jones,et al.  Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). , 2004, Diagnostic microbiology and infectious disease.

[22]  J. Bartlett,et al.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. N. Brogden,et al.  Meropenem , 2012, Drugs.

[24]  R. Jones.  The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. , 1996, Diagnostic microbiology and infectious disease.

[25]  D. Nicolau,et al.  Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002 , 2004, Antimicrobial Agents and Chemotherapy.

[26]  S. Ichiyama,et al.  Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems , 1996, Antimicrobial agents and chemotherapy.

[27]  P. Courvalin,et al.  Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. , 2000, The Journal of antimicrobial chemotherapy.

[28]  J. R. Edwards.  Meropenem: a microbiological overview. , 1995, The Journal of antimicrobial chemotherapy.

[29]  Ronald N. Jones,et al.  Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). , 2008, Microbial drug resistance.

[30]  Ronald N. Jones,et al.  Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). , 2007, Diagnostic microbiology and infectious disease.

[31]  D. Felmingham,et al.  PROTEKT Years 1-3 (1999-2002): Study Design and Methodology , 2004, Journal of chemotherapy.

[32]  Ronald N. Jones,et al.  Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). , 2006, Diagnostic microbiology and infectious disease.

[33]  Ronald N. Jones,et al.  Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. , 2008, Diagnostic microbiology and infectious disease.

[34]  Ronald N. Jones,et al.  MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. , 2000, The Journal of antimicrobial chemotherapy.

[35]  Ronald N. Jones,et al.  Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). , 2007, Diagnostic microbiology and infectious disease.

[36]  P. Turner,et al.  The MYSTIC (meropenem yearly susceptibility test information collection) programme. , 1999, International journal of antimicrobial agents.

[37]  M. Pfaller,et al.  A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. , 1997, Diagnostic microbiology and infectious disease.

[38]  D. Nicolau,et al.  Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem , 2003, Journal of clinical pharmacology.

[39]  Jones.  Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. , 2000, The Journal of antimicrobial chemotherapy.

[40]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[41]  M. Pfaller,et al.  Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). , 2001, Diagnostic microbiology and infectious disease.

[42]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[43]  D. Paterson.  Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  P. Turner.  Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003). , 2004, Diagnostic microbiology and infectious disease.

[45]  R. Jones,et al.  blaVIM-2 and blaVIM-7 Carbapenemase-Producing Pseudomonas aeruginosa Isolates Detected in a Tertiary Care Medical Center in the United States: Report from the MYSTIC Program , 2006, Journal of Clinical Microbiology.

[46]  R N Jones.  Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. , 2000, The Journal of antimicrobial chemotherapy.

[47]  P. Rhomberg,et al.  Comparative Antimicrobial Potency of Meropenem Tested Against Gram-Negative Bacilli: Report from the MYSTIC Surveillance Program in the United States (2004) , 2005, Journal of chemotherapy.

[48]  D. Hoban,et al.  Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. , 2009, International journal of antimicrobial agents.

[49]  Ronald N. Jones,et al.  A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India. , 2002, International journal of antimicrobial agents.

[50]  K. Bush,et al.  Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[51]  R. Gaynes,et al.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  V. Miriagou,et al.  Imipenem Resistance in a Salmonella Clinical Strain Due to Plasmid-Mediated Class A Carbapenemase KPC-2 , 2003, Antimicrobial Agents and Chemotherapy.

[53]  Ronald N. Jones,et al.  Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). , 2004, Diagnostic microbiology and infectious disease.

[54]  Masterton.  Surveillance studies: how can they help the management of infection? , 2000, Journal of Antimicrobial Chemotherapy.

[55]  John Quale,et al.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. , 2005, Archives of internal medicine.

[56]  Philip J Turner.  Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study. , 2005, Diagnostic microbiology and infectious disease.

[57]  P. Bradford,et al.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  Ronald N. Jones.  Global Epidemiology of Antimicrobial Resistance among Community-Acquired and Nosocomial Pathogens: A Five-Year Summary from the SENTRY Antimicrobial Surveillance Program (1997-2001) , 2003, Seminars in respiratory and critical care medicine.

[59]  Ronald N. Jones,et al.  Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). , 2006, Diagnostic microbiology and infectious disease.

[60]  D. Landman,et al.  Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. , 2002, Archives of internal medicine.

[61]  Ronald N. Jones,et al.  Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. , 2004, International journal of antimicrobial agents.

[62]  Ronald N. Jones,et al.  Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. , 2002, Diagnostic microbiology and infectious disease.